Distribution of doses to organs at risk in Cervical Cancer High Dose Rate Brachytherapy using Tandem and Ovoids or Vaginal Cylinder

2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023 (197-200)

АУТОР(И) / AUTHOR(S): Tatjana B. Miladinović, Jasmina Obradović, Marija Živković Radojević, Neda Milosavljević, Aleksandar Miladinović, Milena Živković, Dragana Krstić

Е-АДРЕСА / E-MAIL: tanja.miladinovic@uni.kg.ac.rs

Download Full Pdf   

DOI: 10.46793/ICCBI23.197M

САЖЕТАК / ABSTRACT:

Brachytherapy is an integral part of the treatment of cervical cancer. In brachytherapy, the dose delivered to the tissue is determined primarily by the inverse square law thus the dose decreases rapidly as the distance from the source increases. Therefore, an important role in dose distribution is the geometry of the applicator. A patient’s anatomy as well as the fact that the patient may have been operated on must also be taken into account when selecting the applicator.
The aim of this study was to assess the influence of the type of cervical cancer brachytherapy applicators (tandem and ovoids or vaginal cylinder) on the dose delivered to adjacent organs, urinary bladder, and rectum. The treatment plans of 10 patients with cervical cancer treated by intracavitary brachytherapy were reviewed, and dose distribution data was collected. Prescribed doses were 7 Gy (or 8 Gy)/fractions, and the number of fractions was from 3 to 5, thus cumulative target EQD2 was between 85-90 Gy. Deliveries of doses to the rectum and bladder were controlled within the tolerance ranges. It was found that the selection of the applicator and the doses administered to the bladder and rectum were correlated. Tandem and ovoid applicators produced lower doses in the bladder and rectum by approximately 20% than the vaginal cylinder. The results of this analysis may potentially enable the optimization of dose distribution for organs at risk in each individual clinical situation.

КЉУЧНЕ РЕЧИ / KEYWORDS:

brachytherapy, cervical cancer, applicators, tandem and ovoids, vaginal cylinder

ЛИТЕРАТУРА / REFERENCES:

  •  https://cutt.ly/KCeMB11
  • C.A. Burmeister, S.F. Khan, G. Schäfer, N. Mbatani, T. Adams, J. Moodley, S. Prince., Cervical cancer therapies: Current challenges and future perspectives, Tumour Virus Res, 13 (2022) 200238.
  • J.F. Williamson., Brachytherapy technology and physics practice since 1950: a half-century of progress, Phys. Med. Biol., 50 (2006) R303–R325.
  • Y. Roussakis, G. Anagnostopoulos., Physical and Dosimetric Aspects of the Iridium-Knife, Frontiers in Oncology, 11 (2021) 728452.
  • https://www-pub.iaea.org/mtcd/publications/pdf/te_1257_prn.pdf
  • C. Baker, S.A. Dini, M. Kudrimoti, S.B. Awan,A.S. Meigooni., Dosimetric evaluation of a newly designed low dose rate brachytherapy applicator for treatment of cervical cancer with extension into the lower vagina, J Appl Clin Med Phys., 8 (2007) 37–46.
  • A.A. Khan, A. Vijay, S. Qamar Wani, M.M. Haq., Dosimetric analysis of intracavitary brachytherapy applicators: a practical study, Radiat Oncol J., 40(3) (2022) 180-191.
  • M. Jreij, A. El Ahmar, P. Finianos., Applicators used for vaginal high dose rate brachytherapy: Effect of type and shape on dose distribution and toxicity, a literature review, Cancer/Radiothérapie, 27 (1) (2023) 80-85.
  • S.M. Bentzen, W. Dörr, R. Gahbauer, R.W. Howell, M.C. Joiner, B. Jones, D.T. Jones, A.J. van der Kogel, A. Wambersie, G. Whitmore., Bioeffect modeling and equieffective dose concepts in radiation oncology-terminology, quantities and units, Radiother Oncol, 105(2) (2012) 266-268.
  • JASP Team (2021). JASP (Version 0.16)[Computer software].